Senior Director, New Product Development
James D. (J.D.) Pipkin, Ph.D., is Senior Director, New Product
Development at Ligand Pharmaceuticals, Inc. In 2001, he joined
CyDex Pharmaceuticals, which was acquired in early 2011 by Ligand.
He is responsible for supporting the development of new
applications, intellectual property and products utilizing
CAPTISOL, whether the application involves new molecular entities
or reformulations of existing drugs for life cycle management.
Prior to joining Ligand Pharmaceuticals he was Executive Director
for CMC Services and Director of Formulation Development at Oread
From 1986 through 1995 Dr. Pipkin was a Research Fellow with
Merck Research Laboratories in the INTERx Research and West Point
PR&D facilities. His area of research interest was in the
design and evaluation of controlled release devices to enhance
therapeutic efficacy and lower systemic burden. He was at The
Squibb Institute for Medical Research from 1980 through 1985, where
he directed the preformulation activities for new chemical
entities. He has contributed to numerous presentations,
publications and patents.
Dr. Pipkin holds a M.S. and Ph.D. in Pharmaceutical Chemistry
from the University of Kansas, and a B.A. in Mathematics and
Chemistry, also from the University of Kansas.